ClinicalTrials.gg
RecruitingNCT07216339Updated Jul 27, 2026

Gamification Effects on the 6-Minute Walk Test in Children

An interventional study of Standard 6MWT and Gamified 6MWT in Neuromuscular Diseases in Children, sponsored by David Toupin. Recruiting at 1 site in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by David Toupin · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.

Planned enrollment
53rd of 72
20 · median 48
Started
2026
with 9 others
No phase
23 of 120
5 open now
Primary completion
2027-06
later than 17 of 38 live
Registered
108th of 120
by date

Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 53rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2026, is one of 23 with no phase, reaches primary completion later than 17 of the 38 other live ones, and was the 108th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Neuromuscular Diseases with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn if adding a game to the 6-minute walk test for children with neuromuscular disorders will increase enjoyment and motivation to complete the test.

03

Conditions studied

  • Neuromuscular Diseases in Children

Keywords

  • Gamification
  • Walk Test
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of, or active evaluation for, a neuromuscular disorder
  • Able to ambulate (with or without usual orthoses/assistive device) sufficiently to attempt a 6-minute walk.
  • Note: Acceptable if the patient needs to take breaks or sit during the test. Those unable to finish are counted as protocol deviations, not exclusions.
  • Medically stable on the test day (no acute illness or recent surgery that would contraindicate moderate exercise).
  • Child able to understand simple instructions in English and provide assent (if applicable based upon age and developmental level); parent/guardian able to provide consent in English.

Exclusion criteria

Exclusion Criteria:

  • Non-ambulatory or unsafe to attempt walking as judged by the treating physician.
  • Severe cognitive/behavioral impairment that precludes following instructions.
  • Acute cardiopulmonary, orthopedic, or other medical condition that makes walking unsafe on the test day.
  • Non-English-speaking family (materials are available only in English for this pilot).
  • Any child/parent who declines consent/assent or withdraws at any time.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Gamified test

    child carries a Radio-frequency identification (RFID) tag to scan at each lap, watching avatar level up.

    Other: Gamified 6MWT

  • Active comparator
    Standard test

    no game; same verbal cue every minute

    Other: Standard 6MWT

Interventions

  • OtherStandard 6MWT

    ATS-standard instructions, no electronic system; Conducted in hallway measuring total length of 90ft (27.4 meters). Patients will walk down-and-back. A seated rest period of ≥10 min separates the two tests to minimize fatigue carry-over.

  • OtherGamified 6MWT

    identical course but child carries a RFID tag; at each lap the child taps an on an RFID reader, awarding a point and leveling-up an on-screen avatar; Conducted in hallway measuring total length of 90ft (27.4 meters). Patients will walk down-and-back.A seated rest period of ≥10 min separates the two tests to minimize fatigue carry-over.

06

What researchers measure

Primary outcomes

  1. Change in 6 minute walk distance

    Participants will walk back and forth in the clinic hallway for 6 minutes and distance will be recorded in meters

    Time frame: Baseline and post intervention (approximately 20 minutes)

Secondary outcomes

  1. Change in Children's OMNI Rate of Perceived Exertion (RPE) Scale

    The OMNI RPE scale is a visual and numerical tool from 0-10 that helps individuals subjectively gauge the intensity of walking or running activity, with 0 representing no effort and 10 being maximal exertion.

    Time frame: Baseline and post intervention (approximately 20 minutes)

  2. Change in Physical Activity Enjoyment Scale (PACES)

    The Physical Activity Enjoyment Scale (PACES) consists of 8 questions scored on a scale from 1 to 7, with a maximum score of 56 and a minimum score of 8. Higher scores indicate greater enjoyment of physical activity.

    Time frame: Baseline and post intervention (approximately 20 minutes)

  3. Recruitment Rate

    percent of eligible participants successfully recruited in the study

    Time frame: 9 months

  4. Test completion rate

    number of walk tests successfully completed compared to overall number of walk tests

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 75 non-industry interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 84 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2025
First posted
Oct 14, 2025
StartActual
Jun 12, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07216339
Lead sponsor
David Toupin
Responsible party
David Toupin (Assistant Professor, University of Kentucky) — Sponsor-investigator
First posted
Oct 14, 2025
Start date
Jun 12, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

David N Toupin, MD
Contact
d.n.toupin@uky.edu
859-218-1900
David N Toupin, MD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion